100716-09-4

Basic information

• Product Name: N-((4-bromophenyl)carbamoyl)-4-methylbenzenesulfonamide
• Synonyms: N-((4-bromophenyl)carbamoyl)-4-methylbenzenesulfonamide
• CAS NO: 100716-09-4
• Molecular Weight: 369.239
• Mol File: 100716-09-4.mol
• Article Data: 4

Chemical Properties

• Melting Point: 188-189 °C
• Density: 1.581±0.06 g/cm3(Predicted)
• CAS DataBase Reference: N-((4-bromophenyl)carbamoyl)-4-methylbenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-((4-bromophenyl)carbamoyl)-4-methylbenzenesulfonamide(100716-09-4)
• EPA Substance Registry System: N-((4-bromophenyl)carbamoyl)-4-methylbenzenesulfonamide(100716-09-4)

Safety Data

• Hazardous Substances Data: 100716-09-4(Hazardous Substances Data)

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 4083-64-1 Tosyl isocyanate 
• 106-40-1 4-bromo-aniline 

Relevant articles and documents

Product-Derived Bimetallic Palladium Complex Catalyzes Direct Carbonylation of Sulfonylazides

A novel product-derived bimetallic palladium complex catalyzes a sulfonylazide-transfer reaction with the σ-donor/π-acceptor ligand CO, and is advantageous given its broad substrate scope, high efficiency, and mild reaction conditions (atmospheric pressure of CO at room temperature). This methodology provides a new approach to sulfonylureas, which are present in both pharmaceuticals and agrochemicals. The synthesis of Glibenclamide on a gram scale further revealed the practical utility of this procedure. Mechanistically, the generation of a bridged bimetallic palladium species derived from the product sulfonylurea is disclosed as the crucial step for this catalytic cycle.

Novel agents effective against solid tumors: The diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships

A series of diarylsulfonylureas with exceptionally broad-spectrum activity against syngeneic rodent solid tumors in vivo is described. Their discovery resulted from a program dedicated to in vivo screening for novel oncolytics in solid tumor models, rather than traditional ascites leukemia models. The structures, oral efficacy, side-effect profile, and mechanism of action of these sulfonylureas appear to be distinct from previously known classes of oncolytics. An extensive series of analogues was prepared to probe structure-activity relationships (SAR), with particular focus on the substituent patterns of each aryl domain. Quantitative analysis of these substituent SARs, using the method of cluster significance analysis, showed the lipophilicity of the substituents to be the dominant determinant of activity. One compound from the series, LY186641 (104, sulofenur), has progressed to Phase I clinical trials as an antitumor drug.